{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:39:53Z","timestamp":1792773593305,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["25ck0106917"],"award-info":[{"award-number":["25ck0106917"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.esmoop.2026.108282","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:19:33Z","timestamp":1784611173000},"page":"108282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of trastuzumab emtansine in patients with advanced human epidermal growth factor receptor 2-positive extramammary Paget\u2019s disease: an investigator-initiated, open-label, single-arm, multicentre, prospective, phase II clinical trial (TEMENOS-2)"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2755-5818","authenticated-orcid":false,"given":"S.","family":"Arakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3069-1546","authenticated-orcid":false,"given":"I.","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0658-6973","authenticated-orcid":false,"given":"Y.","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2526-3504","authenticated-orcid":false,"given":"H.","family":"Uchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9360-5994","authenticated-orcid":false,"given":"T.","family":"Isei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6818-944X","authenticated-orcid":false,"given":"T.","family":"Takenouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5631-8112","authenticated-orcid":false,"given":"S.","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6969-1653","authenticated-orcid":false,"given":"T.","family":"Takai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6082-4696","authenticated-orcid":false,"given":"S.","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6809-5833","authenticated-orcid":false,"given":"T.","family":"Fujimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9317-7267","authenticated-orcid":false,"given":"Y.","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2934-3692","authenticated-orcid":false,"given":"T.","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3733-7411","authenticated-orcid":false,"given":"R.","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8893-4590","authenticated-orcid":false,"given":"T.","family":"Funakoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2026.108282_bib1","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1001\/jamaoncol.2021.7148","article-title":"Evidence-based clinical practice guidelines for extramammary Paget disease","volume":"8","author":"Kibbi","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2026.108282_bib2","article-title":"Incidence and survival of extramammary Paget\u2019s disease from the Surveillance, Epidemiology, and End Results (SEER) database","volume":"1","author":"Nicaise","year":"2024","journal-title":"Surg Oncol Insight"},{"key":"10.1016\/j.esmoop.2026.108282_bib3","first-page":"313","article-title":"Extramammary Paget\u2019s disease: treatment, prognostic factors and outcome in 76 patients","volume":"158","author":"Hatta","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.esmoop.2026.108282_bib4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jdermsci.2015.03.014","article-title":"The role of sentinel lymph node biopsy in the management of invasive extramammary Paget\u2019s disease: multi-center, retrospective study of 151 patients","volume":"79","author":"Fujisawa","year":"2015","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.esmoop.2026.108282_bib5","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jdermsci.2016.06.004","article-title":"A proposal for a TNM staging system for extramammary Paget disease: retrospective analysis of 301 patients with invasive primary tumors","volume":"83","author":"Ohara","year":"2016","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.esmoop.2026.108282_bib6","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.3390\/cancers14143519","article-title":"HER2-targeted antibody-drug conjugates display potent antitumor activities in preclinical extramammary Paget\u2019s disease models: in vivo and immunohistochemical analyses","volume":"14","author":"Tokuchi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2026.108282_bib7","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s11912-023-01434-0","article-title":"Extramammary Paget disease: a therapeutic challenge, for a rare entity","volume":"25","author":"P\u00e9rez","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.esmoop.2026.108282_bib8","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ygyno.2007.12.014","article-title":"HER-2\/neu targeting for recurrent vulvar Paget\u2019s disease: a case report and literature review","volume":"111","author":"Karam","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.esmoop.2026.108282_bib9","article-title":"Dramatic clinical response of relapsed metastatic extramammary Paget\u2019s disease to trastuzumab monotherapy","volume":"2012","author":"Wakabayashi","year":"2012","journal-title":"Case Rep Dermatol Med"},{"key":"10.1016\/j.esmoop.2026.108282_bib10","article-title":"Metastatic extramammary Paget\u2019s disease of scrotum responds completely to single agent trastuzumab in a hemodialysis patient: case report, molecular profiling and brief review of the literature","volume":"2015","author":"Barth","year":"2015","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.esmoop.2026.108282_bib11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.4103\/0019-5154.160541","article-title":"Extramammary Paget\u2019s disease in two brothers","volume":"60","author":"Zhang","year":"2015","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.esmoop.2026.108282_bib12","article-title":"Treatment of invasive Paget\u2019s disease of the vulva in pregnancy: a case report","volume":"33","author":"Bruce","year":"2020","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.esmoop.2026.108282_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf063","article-title":"Antibody-drug conjugate (disitamab vedotin) therapy targeting HER2-low or higher advanced extramammary Paget\u2019s disease","volume":"30","author":"Zhang","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2026.108282_bib14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: mechanisms of action and drug resistance","volume":"16","author":"Barok","year":"2024","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108282_bib15","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108282_bib16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108282_bib17","series-title":"KADCYLA (ado-trastuzumab emtansine) Prescribing Information","year":"2025"},{"key":"10.1016\/j.esmoop.2026.108282_bib18","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108282_bib19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/jjco\/hyw013","article-title":"A multicenter phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer","volume":"46","author":"Kashiwaba","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108282_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/jnci\/95.1.19","article-title":"Placebo effects in oncology","volume":"95","author":"Chvetzoff","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2026.108282_bib21","doi-asserted-by":"crossref","first-page":"e795","DOI":"10.1111\/1346-8138.17855","article-title":"Japanese Dermatological Association Guidelines: Clinical questions of guidelines for extramammary Paget disease 2025","volume":"52","author":"Matsushita","year":"2025","journal-title":"J Dermatol"},{"key":"10.1016\/j.esmoop.2026.108282_bib22","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000445827","article-title":"Human epidermal growth factor receptor 2 (HER-2\/neu)-directed therapy for rare metastatic epithelial tumors with HER-2 amplification","volume":"9","author":"Shin","year":"2016","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.esmoop.2026.108282_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00204","article-title":"Case of metastatic extramammary Paget disease of the vulva treated successfully with trastuzumab emtansine","volume":"2","author":"Hsieh","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2026.108282_bib24","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4103\/ds.ds_9_20","article-title":"Ado-trastuzumab emtansine (T-DM1) for a case of HER2-amplified metastatic extramammary Paget\u2019s disease of scrotum: clinical next-generation sequencing for precision medicine","volume":"38","author":"Chen","year":"2020","journal-title":"Dermatol Sin"},{"key":"10.1016\/j.esmoop.2026.108282_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108282_bib26","doi-asserted-by":"crossref","first-page":"e1201","DOI":"10.1093\/oncolo\/oyae097","article-title":"Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget\u2019s disease (EMPD-HER2DOC)","volume":"29","author":"Hirai","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2026.108282_bib27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bjd.17789","article-title":"Serum cytokeratin 19 fragment 21-1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget disease","volume":"181","author":"Nakamura","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.esmoop.2026.108282_bib28","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.7150\/jca.86746","article-title":"Adverse event profile differences between trastuzumab emtansine and trastuzumab deruxtecan: a real-world, pharmacovigilance study","volume":"14","author":"Liu","year":"2023","journal-title":"J Cancer"},{"key":"10.1016\/j.esmoop.2026.108282_bib29","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108282_bib30","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3390\/cancers13051015","article-title":"The exciting new field of HER2-low breast cancer treatment","volume":"13","author":"Eiger","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2026.108282_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101615","article-title":"Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer","volume":"8","author":"Viale","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.108282_bib32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/ajd.14490","article-title":"HER2 expression and its correlation with clinicopathological features and prognosis in extramammary Paget\u2019s disease: a systematic review and meta-analysis","volume":"66","author":"Ram\u00edrez-Clavijo","year":"2025","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.esmoop.2026.108282_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000279","article-title":"Activating HER2 mutations as emerging targets in multiple solid cancers","volume":"2","author":"Connell","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.108282_bib34","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1111\/1346-8138.16439","article-title":"Clinical significance of ERBB2 S310F mutation in extramammary Paget\u2019s disease","volume":"49","author":"Kusaba","year":"2022","journal-title":"J Dermatol"},{"key":"10.1016\/j.esmoop.2026.108282_bib35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jdermsci.2025.08.001","article-title":"Prevalence of FOXA1 and ERBB2 activating mutations in extramammary Paget\u2019s disease: A retrospective multicenter analysis of 99 cases from Japanese and Taiwanese cohorts","volume":"120","author":"Omi","year":"2025","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.esmoop.2026.108282_bib36","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.6004\/jnccn.2015.0132","article-title":"Prolonged response to trastuzumab in a patient with HER2-nonamplified breast cancer with elevated HER2 dimerization harboring an ERBB2 S310F mutation","volume":"13","author":"Chumsri","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.esmoop.2026.108282_bib37","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.clbc.2016.08.001","article-title":"A rare case of S310F somatic ERBB2 mutation in a HER2-nonamplified breast cancer","volume":"17","author":"Jasra","year":"2017","journal-title":"Clin Breast Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:40:22Z","timestamp":1792770022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926022246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2059702926022246"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108282","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of trastuzumab emtansine in patients with advanced human epidermal growth factor receptor 2-positive extramammary Paget\u2019s disease: an investigator-initiated, open-label, single-arm, multicentre, prospective, phase II clinical trial (TEMENOS-2)","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108282","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108282"}}